Nutritional and pharmacological management of pediatric obesity: a multiprofissional treatment

Authors

DOI:

https://doi.org/10.33448/rsd-v10i1.11797

Keywords:

Pediatric obesity; Diet Therapy; Pharmacological treatment.

Abstract

Pediatric obesity, when left untreated, tends to generate several complications that can extend into adulthood. Proper management allows good results, providing better quality of life to patients. In this context, the objective of this study was to investigate the main nutritional and pharmacological therapies used in this condition. A systematic review of the literature was carried out, based on the search for scientific articles indexed in PubMed, ScienceDirect and Scielo, using the following descriptors: pediatric obesity, treatment, sibutramine, orlistate, liraglutide and breastfeeding, as well as their translations into English. Healthy eating habits, associated with the practice of physical exercises, are considered effective treatment strategies, even for cases of severe obesity, and well-structured nutritional monitoring is indispensable for therapeutic success. Anti-obesity drugs, on the other hand, are resources used when changes in lifestyle alone are not sufficient to achieve satisfactory results. According to the Brazilian Society of Pediatrics, the most recommended pharmacotherapeutic possibilities are sibutramine, orlistat and liraglutide. However, these agents, despite triggering beneficial effects, can generate adverse events, requiring the constant monitoring of patients. Thus, it is extremely important that the prescriber makes a rigorous assessment of the risks and benefits provided by the available anti-obesity pharmacotherapy, in addition to beneficial activities developed by the multidisciplinary health team for the improvement of the child's habits, aiming at maintaining long-term results.

References

Barros, A. M. G., Visco, D. B., da Silva, R. M. P., da Paiva Alves, S. P., da Silva Simões, M. O., Medeiros, C. C. M., & de Carvalho, D. F. (2020). Perfil lipídico em crianças com sobrepeso e obesidade: uma revisão integrativa. Research, Society and Development, 9(11), e4349119952-e4349119952.

Berkowitz, R. I., Fujioka, K., Daniels, S. R., Hoppin, A. G., Owen, S., Perry, A. C., Sothern, M. S., Renz, C. L., Pirner, M. A., Walch, J. K., Jasinsky, O., Hewkin, A. C., & Blakesley, V. A. (2006). Effects of sibutramine treatment in obese adolescents: a randomized trial. Annals of internal medicine, 145(2), 81-90.

Berkowitz, R. I., Wadden, T. A., Tershakovec A. M., & Cronquist J. L. (2003). Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA, 289(14), 1805-1812.

Brasil. (2016). Liraglutida é aprovada como tratamento auxiliar para o controle do peso em adultos. Obtido em https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2016/liraglutida-e-aprovada-como-tratamento-auxiliar-para-o-controle-do-peso-em-adultos.

Brasil. (2018). Brasil supera baixo peso infantil, mas número de crianças e adolescentes com sobrepeso e obesidade é preocupante, diz ministra Ideli. Obtido em https://www.gov.br/mdh/pt-br/sdh/noticias/2015/marco/brasil-supera-baixo-peso-infantil-mas-numero-de-criancas-e-adolescentes-com-sobre-peso-e-obesidade-e-preocupante-diz-ministra-ideli.

Brasil. (2020a). Data lembra importância de combater a obesidade infantil. Obtido em https://www.gov.br/pt-br/noticias/saude-e-vigilancia-sanitaria/2020/06/data-lembra-importancia-de-combater-a-obesidade-infantil.

Brasil. (2020b). Saxenda (liraglutida): nova indicação. Obtido em https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/saxenda-liraglutida-nova-indicacao.

Camacho, W. J. M., Díaz, J. M. M., Ortiz, S. P., Ortiz, J. E. P., Camacho, M. A. M., & Calderón, B. P. (2019). Childhood obesity: aetiology, comorbidities, and treatment. Diabetes/metabolism research and reviews, 35(8), e3203.

Chanoine, J. P., Hampl, S., Jensen, C., Boldrin, M., & Hauptman, J. (2005). Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA, 293(23), 2873-2883.

Chao, A. M., Wadden, T. A., & Berkowitz, R. I. (2018). The safety of pharmacologic treatment for pediatric obesity. Expert opinion on drug safety, 17(4), 379-385.

Daniels, S. R., & Hassink, S. G. (2015). The role of the pediatrician in primary prevention of obesity. Pediatrics, 136(1), e275-e292.

Danne, T., Biester, T., Kapitzke, K., Jacobsen, S. H., Jacobsen, L. V., Petri, K. C. C., Hale, P. M., & Kordonouri, O. (2017). Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. The journal of pediatrics, 181, 146-153.

Franco, R. R., Cominato, L., & Damiani, D. (2014). The effect of sibutramine on weight loss in obese adolescents. Arquivos brasileiros de endocrinologia e metabologia, 58(3), 243-250.

James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Gaal, L. F. V., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., & Renz, C. L. (2010). Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The New England journal of medicine, 363(10), 905-917.

Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020). A randomized, controlled trial of liraglutide for adolescents with obesity. The New England journal of medicine, 382(22), 2117-2128.

Kumar, H., Toit, E. d., Kulkarni, A., Aakko, J., Linderborg, K. M., Zhang, Y., Nicol, M. P., Isolauri, E., Yang, B., Collado, M. C., & Salminen, S. (2016). Distinct patterns in human milk microbiota and fatty acid profiles across specific geographic locations. Frontiers in microbiology, 7, 1619.

Kumar, S., & Kelly, A. S. (2017). Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo clinic proceedings, 92(2), 251-265.

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine, 6(7), e1000100.

Mello, E. D., & Moretzsohn, M. (2019). Tratamento Farmacológico da Obesidade. In Sociedade Brasileira de Pediatria. Manual de Orientação: obesidade na infância e adolescência (3rd ed., pp. 118-131). São Paulo: Departamento Científico de Nutrologia.

Norgren, S., Danielsson, P., Jurold, R., Lötborn, M., & Marcus, C. (2003). Orlistat treatment in obese prepubertal children: a pilot study. Acta paediatrica, 92(6), 666-670.

Pereira, A.S.; Shitsuka, D. M.; Parreira, F. J., & Shitsuka, R. (2018). Construção e validação de instrumentos e técnicas de coleta de dados. In Colusso, P. R. Metodologia da pesquisa científica (1rd ed., pp. 42-43). Santa Maria: UFSM, Núcleo De Tecnologia Educacional.

Rajjo, T., Mohammed, K., Alsawas, M., Ahmed, A. T., Farah, W., Asi, N., Almasri, J., Prokop, L. J., & Murad, M. H. (2017). Treatment of Pediatric Obesity: An Umbrella Systematic Review. The journal of clinical endocrinology and metabolism, 102(3), 763-775.

Ryder, J. R., Fox, C. K., & Kelly, A. S. (2018). Treatment options for severe obesity in the pediatric population: current limitations and future opportunities. Obesity, 26(6), 951-960.

Sanchez, M., Panahi, S., & Tremblay, A. (2015). Childhood obesity: a role for gut microbiota? International journal of environmental research and public health, 12(1), 162-175.

Sivamaruthi, B. S., Kesika, P., Suganthy, N., & Chaiyasut, C. (2019). A review on role of microbiome in obesity and antiobesity properties of probiotic supplements. BioMed research international, 2019, 3291367.

Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017). Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline. The journal of clinical endocrinology and metabolism, 102(3), 709-757.

Viner, R. M., Hsia, Y., Tomsic, T., & Wong, I. C. K. (2010). Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obesity reviews: an official journal of the International Association for the Study of Obesity, 11(8), 593-602.

Wickham 3rd, E. P., & DeBoer, M. D. (2015). Evaluation and treatment of severe obesity in childhood. Clinical pediatrics, 54(10), 929-940.

World Health Organization. (2020). Obesity and overweight. Retrieved October 1, 2020, from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

Yan, J., Liu, L., Zhu, Y., Huang, G., & Wang, P. P. (2014). The association between breastfeeding and childhood obesity: a meta-analysis. BMC public health, 14(1), 1267.

Yang, B. G., Hur, K. Y., & Lee, M. S. (2017). Alterations in gut microbiota and immunity by dietary fat. Yonsei medical journal, 58(6), 1083-1091.

Published

26/01/2021

How to Cite

GUSMÃO, A. B. de .; ROCHA, S. de S. .; FERREIRA, B. W. R. C. .; SANTOS, A. K. F. de S. .; MACEDO, C. L. . Nutritional and pharmacological management of pediatric obesity: a multiprofissional treatment. Research, Society and Development, [S. l.], v. 10, n. 1, p. e60010111797, 2021. DOI: 10.33448/rsd-v10i1.11797. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/11797. Acesso em: 1 mar. 2021.

Issue

Section

Health Sciences